PET Imaging of Inflammation and Lipid Lowering Study

Inclusion Criteria: * Male or female participants \>18 years old * Able to give written, informed consent and to lie flat * Have primary hypercholesterolaemia (non-familial or definite or possible heterozygous familial hypercholesterolaemia (HeFH) based on clinical criteria) or mixed dyslipidaemia, and * History of CVD (acute coronary syndrome, coronary or other revascularisation procedures, coronary heart disease, ischaemic stroke, or peripheral arterial disease) and elevated LDL cholesterol ≥2.6 despite maximum tolerated statins with or without other lipid lowering therapies (see NICE TA 733), and * Lipid lowering therapy unchanged for at least 6 weeks prior to screening, and * Pre-existing carotid atherosclerotic plaque ≥15mm by B-mode ultrasound Exclusion Criteria: * Women of childbearing potential not using adequate contraception * Contra-indication to MRI scanning * Statin-associated myositis or liver function abnormality * Already taking inclisiran or colchicine * Sensitivity and/or contraindication to inclisiran or colchicine. Contraindications to colchicine include severe hepatic or renal impairment, blood disorders, and patients with renal or hepatic impairment who are taking a P-gp inhibitor or a strong CYP3A4 inhibitor * Contrast allergy or contrast-nephropathy * Chronic kidney disease (eGFR \<30 mL/min/1.73 m2) * Cardiovascular event within 6 months * Any medical condition, in the opinion of the investigator, that prevents the participant from lying flat during scanning, or from participating in the study * Uncontrolled chronic inflammatory disorder * History of recent malignancy deemed relevant to the study by the investigator * Treatment with medications that result in significant drug to drug interactions with the study medications * Current use of systemic corticosteroids or other immunosuppressive drugs * Previous or planned carotid endarterectomy surgery or stenting on the index side